Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations

Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations

IntroductionNatalizumab is a biologic drug for relapsing-remitting multiple sclerosis that may induce the generation of anti-drug antibodies in some patients. Anti-natalizumab antibodies (ANA) increase the risk of adverse events and reduce efficacy, being useful biomarkers for monitoring treatment r...

Full description

Bibliographic Details
Main Authors: Nicolás Lundahl Ciano-Petersen, Pablo Aliaga-Gaspar, Isaac Hurtado-Guerrero, Virginia Reyes, José Luis Rodriguez-Bada, Eva Rodriguez-Traver, Isabel Brichette-Mieg, Laura Leyva Fernández, Pedro Serrano-Castro, Ana Alonso, Begoña Oliver-Martos
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Immunology
Subjects:
multiple sclerosis
natalizumab
immunogenicity
anti-drug antibodies
adverse events
exacerbations
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1242508/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1242508/full

Similar Items